Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis
- PMID: 19386576
- PMCID: PMC2963055
- DOI: 10.1093/schbul/sbp031
Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis
Abstract
Objective: Our aim was to review recent studies and estimate the rate of cannabis use disorders (CUDs) in schizophrenia, as well as to examine the factors affecting this rate.
Methods: We conducted an electronic search of 3 literature databases and a manual search of articles from 1996 to 2008. The key words used were "schizophreni*," "psychos*s," "psychotic," "cannabis abuse," "cannabis dependence," "cannabis use disorder," "substance use disorder," "substance abuse," "substance dependence," and "dual diagnosis." Articles that reported diagnoses according to the Diagnostic and Statistical Manual of Mental Disorders or International Classification of Diseases were included. Regression analysis was used to examine how estimated rates of CUDs are affected by various study characteristics such as the classification system, inpatient vs outpatient status, study location, proportion of males, age of the sample, or duration of illness.
Results: Thirty-five studies met our search criteria. The median current rate of CUDs was 16.0% (interquartile range [IQR] = 8.6-28.6, 10 studies), and the median lifetime rate was 27.1% (IQR = 12.2-38.5, 28 studies). The median rate of CUDs was markedly higher in first-episode vs long-term patients (current 28.6%/22.0%, lifetime 44.4%/12.2%, respectively) and in studies where more than two-thirds of the participants were males than in the other studies (33.8%/13.2%). CUDs were also more common in younger samples than in the others (current 38.5%/16.0%, lifetime 45.0%/17.9%).
Conclusions: Approximately every fourth schizophrenia patient in our sample of studies had a diagnosis of CUDs. CUDs were especially common in younger and first-episode patient samples as well as in samples with a high proportion of males.
Figures
Similar articles
-
[Cannabis and schizophrenia: demographic and clinical correlates].Encephale. 2003 Jan-Feb;29(1):11-7. Encephale. 2003. PMID: 12640322 French.
-
Craving in patients with schizophrenia and cannabis use disorders.Can J Psychiatry. 2013 Nov;58(11):646-9. doi: 10.1177/070674371305801111. Can J Psychiatry. 2013. PMID: 24246436
-
Cannabis use and cannabis use disorders among individuals with mental illness.Compr Psychiatry. 2013 Aug;54(6):589-98. doi: 10.1016/j.comppsych.2012.12.021. Epub 2013 Jan 31. Compr Psychiatry. 2013. PMID: 23375264
-
What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis.Addict Behav. 2020 Oct;109:106479. doi: 10.1016/j.addbeh.2020.106479. Epub 2020 May 20. Addict Behav. 2020. PMID: 32485547
-
The impact of cannabis and stimulant disorders on diagnostic stability in psychosis.J Clin Psychiatry. 2014 Apr;75(4):349-56. doi: 10.4088/JCP.13m08878. J Clin Psychiatry. 2014. PMID: 24813404 Review.
Cited by
-
A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches.Ann Gen Psychiatry. 2015 Dec 10;14:44. doi: 10.1186/s12991-015-0083-x. eCollection 2015. Ann Gen Psychiatry. 2015. PMID: 26692885 Free PMC article.
-
The relationship between substance use and self-reported aspects of social functioning in patients with a psychotic disorder.Eur Psychiatry. 2024 Feb 29;67(1):e21. doi: 10.1192/j.eurpsy.2024.9. Eur Psychiatry. 2024. PMID: 38418416 Free PMC article.
-
Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.Lancet Psychiatry. 2017 Aug;4(8):627-633. doi: 10.1016/S2215-0366(17)30233-X. Epub 2017 Jul 10. Lancet Psychiatry. 2017. PMID: 28705600 Free PMC article.
-
Behavioral interventions for antipsychotic induced appetite changes.Curr Psychiatry Rep. 2013 Mar;15(3):347. doi: 10.1007/s11920-012-0347-y. Curr Psychiatry Rep. 2013. PMID: 23404388 Free PMC article.
-
A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.J Dual Diagn. 2011;7(1-2):50-63. doi: 10.1080/15504263.2011.570118. J Dual Diagn. 2011. PMID: 25914610 Free PMC article.
References
-
- Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16:31–55. - PubMed
-
- Cantor-Graae E, Nordström LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res. 2001;48:69–82. - PubMed
-
- Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;28:319–328. - PubMed
-
- Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry. 2000;34:468–475. - PubMed
-
- Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35:S93–S100. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous